These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

259 related items for PubMed ID: 10514023

  • 1. Comparative safety and tolerability of clopidogrel and aspirin: results from CAPRIE. CAPRIE Steering Committee and Investigators. Clopidogrel versus aspirin in patients at risk of ischaemic events.
    Harker LA, Boissel JP, Pilgrim AJ, Gent M.
    Drug Saf; 1999 Oct; 21(4):325-35. PubMed ID: 10514023
    [Abstract] [Full Text] [Related]

  • 2. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    CAPRIE Steering Committee.
    Lancet; 1996 Nov 16; 348(9038):1329-39. PubMed ID: 8918275
    [Abstract] [Full Text] [Related]

  • 3. Clopidogrel: a review of its use in the prevention of atherothrombosis.
    Jarvis B, Simpson K.
    Drugs; 2000 Aug 16; 60(2):347-77. PubMed ID: 10983738
    [Abstract] [Full Text] [Related]

  • 4. Clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole in the secondary prevention of occlusive vascular events: a systematic review and economic evaluation.
    Jones L, Griffin S, Palmer S, Main C, Orton V, Sculpher M, Sudlow C, Henderson R, Hawkins N, Riemsma R.
    Health Technol Assess; 2004 Oct 16; 8(38):iii-iv, 1-196. PubMed ID: 15461876
    [Abstract] [Full Text] [Related]

  • 5. Thienopyridine derivatives (ticlopidine, clopidogrel) versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients.
    Hankey GJ, Sudlow CL, Dunbabin DW.
    Cochrane Database Syst Rev; 2000 Oct 16; (2):CD001246. PubMed ID: 10796426
    [Abstract] [Full Text] [Related]

  • 6. Results of the CAPRIE trial: efficacy and safety of clopidogrel. Clopidogrel versus aspirin in patients at risk of ischaemic events.
    Creager MA.
    Vasc Med; 1998 Oct 16; 3(3):257-60. PubMed ID: 9892520
    [Abstract] [Full Text] [Related]

  • 7. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial.
    Diener HC, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M, Leys D, Matias-Guiu J, Rupprecht HJ, MATCH investigators.
    Lancet; 1998 Oct 16; 364(9431):331-7. PubMed ID: 15276392
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Generalizing the results of clinical trials to actual practice: the example of clopidogrel therapy for the prevention of vascular events. CAPRA (CAPRIE Actual Practice Rates Analysis) Study Group. Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events.
    Caro JJ, Migliaccio-Walle K.
    Am J Med; 1999 Dec 16; 107(6):568-72. PubMed ID: 10625025
    [Abstract] [Full Text] [Related]

  • 13. Clopidogrel.
    Coukell AJ, Markham A.
    Drugs; 1997 Nov 16; 54(5):745-50; discussion 751. PubMed ID: 9360060
    [Abstract] [Full Text] [Related]

  • 14. From CURE to MATCH: ADP receptor antagonists as the treatment of choice for high-risk atherothrombotic patients.
    Hacke W.
    Cerebrovasc Dis; 2002 Nov 16; 13 Suppl 1():22-6. PubMed ID: 11803184
    [Abstract] [Full Text] [Related]

  • 15. Thienopyridine derivatives versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients.
    Sudlow CL, Mason G, Maurice JB, Wedderburn CJ, Hankey GJ.
    Cochrane Database Syst Rev; 2009 Oct 07; 2009(4):CD001246. PubMed ID: 19821273
    [Abstract] [Full Text] [Related]

  • 16. Costs and consequences of clopidogrel versus aspirin for secondary prevention of ischaemic events in (high-risk) atherosclerotic patients in Sweden: a lifetime model based on the CAPRIE trial and high-risk CAPRIE subpopulations.
    Logman JF, Heeg BM, Herlitz J, van Hout BA.
    Appl Health Econ Health Policy; 2010 Oct 07; 8(4):251-65. PubMed ID: 20578780
    [Abstract] [Full Text] [Related]

  • 17. Value of antiplatelet therapy in preventing thrombotic events in generalized vascular disease.
    Montalescot G.
    Clin Cardiol; 2000 Nov 07; 23 Suppl 6(Suppl 6):VI-18-22. PubMed ID: 11129682
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.